XSUITE
7.8.2024 15:48:31 CEST | Business Wire | Press release
xSuite Nordic, a subsidiary of software manufacturer xSuite Group, invites customers and prospects to its roadshow in Copenhagen/Valby (5.9.24) and Horsens (12.9.24). Participants will be taken on a journey that brings them closer to SAP S/4HANA, Clean Core and the SAP Business Technology Platform (BTP). They will learn how xSuite solutions can be used to set up future-proof P2P processes for SAP S/4HANA. xSuite will also showcase how to combine automation and intuitive workflows for incoming invoice processing based on the clean core principle.
SAP user companies have a lot on their plate these days: Prepare for the migration to S/4HANA, push ahead process digitization and improvement, and move to the cloud. At the roadshow, Bo Bærentsen, Senior Business Consultant, and Michael Francker Christensen, Solution Architect (both from xSuite), will present how xSuite supports organizations on their journey to a clean core, with a focus on P2P processes and SAP S/4HANA.
Maiken Borup-Mikkelsen, People Lead & Director DC, SAP at Deloitte Denmark, talks about the future of work: What does the future of work look like in the SAP context? In Valby, Ólafur Harðarson, IT Application Manager from Síminn Telecommunications Reykjavik Island, will introduce Síminn’s change story “From a lot of SAP to better SAP”.
In Horsens, Charlotte Uhrskov Johansen, Project Lead & Manager Future Finance at Bestseller, will present how the company migrated to S/4HANA globally in order to achieve more automation and efficiency in financial processes. Bestseller is implementing SAP Fiori for all financial processes in the S/4HANA Private Cloud.
Martin Lundsteen, Managing Director of xSuite Nordic, will guide participants through the series of presentations on both dates. Afterwards, xSuite invites guests to a get-together from 12 noon to 1 p.m.
Event information:
Duration of both events: 9:30 a.m. – 1:00 p.m.
The presentations will be given in Danish at both locations.
05.9.24, Copenhagen/Valby
Transformerstationen
Gl. Køge Landevej 18
2500 Valby, Denmark
12.9.24, Horsens
Jorgensens Hotel
Søndergade 17
8700 Horsens, Denmark
More information and registration: https://news.xsuite.com/en/international-roadshow-2024
About xSuite
With offices in Europe, Asia, and the U.S., as well as ample experience across industries and multiple SAP solutions, xSuite is a top innovator in optimizing SAP-based P2P workflows, providing software and implementing solutions for over 1,300 clients. The company has become a trusted partner in modernizing AP systems and automating manual, paper-based processes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807495174/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom